SILVER SPRING
Inqovi plus venetoclax cleared for AML ineligible for intensive chemo
- Sponsor
- Taiho Oncology, Inc.
- Drug
- Inqovi · decitabine/cedazuridine
- Indication
- acute myeloid leukemia ineligible for intensive induction chemotherapy
FDA approved Inqovi (decitabine/cedazuridine) plus venetoclax for acute myeloid leukemia patients ineligible for intensive induction chemotherapy.
What this means
Inqovi is a combination pill that contains two drugs: decitabine, which interferes with cancer cell growth, and cedazuridine, which helps decitabine stay active in the body longer. Today FDA approved Inqovi to be used alongside venetoclax for adults with acute myeloid leukemia who cannot tolerate intensive chemotherapy. This approval gives these patients a new treatment option that may help manage their cancer with a less intensive approach.
Drug Watch — recent news on Inqovi
- FDA Grants Approval for Oral Decitabine and Cedazuridine With Venetoclax in Newly Diagnosed AML - Oncodaily
- Oral decitabine/cedazuridine + venetoclax in ND AML: Phase II long-term follow-up - aml-hub.com
- Phase I/II ASCERTAIN-V trial: Decitabine/cedazuridine + venetoclax in ND AML - aml-hub.com
- All-oral chemotherapy regimen tolerable and efficacious for newly diagnosed acute myeloid leukemia - 2 Minute Medicine
- All-Oral Decitabine/Cedazuridine Combo Enters Frontline AML - CancerNetwork